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with a small prosthetic valve is technically straightfor-
ward and commonly performed, but it may result in a
patient-prosthetic mismatch resulting in a high residual
O ptimal surgical management of aortic valve diseasein the elderly patient with a small aortic root
remains controversial. Aortic valve replacement (AVR)
Objective: Ideal management of the elderly patient with a small aortic
root remains controversial. This retrospective analysis was performed to
determine whether small prosthetic valve size is related to outcome in
patients 70 years of age or older undergoing aortic valve replacement for
aortic stenosis. Methods: Between December 1991 and July 1998, 366
patients 70 years of age or older (median age 77 years, range 73-81
years, 49% male) underwent isolated aortic valve replacement or aortic
valve replacement with coronary bypass grafting with standard
Carpentier-Edwards bovine pericardial valves (Baxter Healthcare
Corp, Edwards Division, Santa Ana, Calif) (n = 277; 76%) or St Jude
Medical mechanical valves (St Jude Medical, Inc, St Paul, Minn) (n = 89;
24%). Propensity scoring and multivariable regression models were
used to evaluate the risks associated with implantation of 19-mm valves.
Results: Operative mortality was 16.7% (17/102) in patients who received
19-mm valves and 3% (8/264) among those receiving ‡ 21-mm valves (P
≤ .0005). The univariable odds ratio for operative death for 19-mm ver-
sus ‡ 21-mm valves was 6.4 (95% CI 2.7, 15.4; P ≤ .0005). In the final
multivariable model, receipt of a 19-mm valve alone was not a statisti-
cally significant predictor of operative death (odds ratio 2.1; 95% CI 0.7,
6.4; P = .21). However, the combination of male sex and 19-mm valve
resulted in a significant risk of operative death (4/9 patients; odds ratio
17.5; 95% CI 2.2, 139; P = .007). Use of a 19-mm valve was not related
to late death in either the univariable (hazard ratio 1.0; 95% CI 0.5, 2.0;
P = .95) or the multivariable analysis (hazard ratio 0.7; 95% CI 0.3, 1.8;
P = .51). Conclusions: Implantation of a standard 19-mm aortic valve in
elderly men with aortic stenosis may be associated with an increased
risk of operative mortality. A higher performance valve and/or a root
enlargement procedure should be considered in men with a measured
19-mm anulus. (J Thorac Cardiovasc Surg 1999;118:815-22)
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outflow gradient, the significance of which remains the
subject of controversy.1-11 Use of stentless valves or
homografts results in lower residual postoperative gra-
dients, but implant procedures are technically more
demanding, leading to increased total ischemic
time.10,12-14 Annular enlargement allows for insertion of
a larger aortic prosthesis, but it too may introduce
increased surgical risks.15,16 For the past several years
our practice at Brigham and Women’s Hospital has
been to size the anulus and insert a standard 19-mm
valve prosthesis when indicated, without annular
enlargement. To clarify the clinical influence of insert-
ing a 19-mm valve in elderly patients, we have exam-
ined our operative and long-term outcomes after AVR
for aortic stenosis with or without concomitant coro-
nary artery bypass grafting (CABG). Since gender may
play a role in operative mortality,17,18 we evaluated our
surgical outcomes in that context.
Patients and methods
Patients. Baseline risk factors and subsequent outcome
were collected in 366 patients with aortic stenosis who were
70 years of age or older undergoing isolated AVR (n = 139;
38%) or AVR combined with CABG (n = 227; 62%) at
Brigham and Women’s Hospital between December 1991 and
July 1998. The median age of patients was 77 years (inter-
quartile range [IQR] 73 to 81 years) and 49% were male. All
patients underwent preoperative cardiac catheterization and
echocardiography. Isolated aortic stenosis was identified in
306 patients (84%), and 60 patients (16%) had combined aor-
tic stenosis and insufficiency. Aortic stenosis was categorized
as severe in 278 patients (76%), moderate in 77 patients
(21%), and mild in 11 patients (3%). AVR prosthesis size (19-
25 mm) and type (Carpentier-Edwards bovine pericardial
valve [Baxter Healthcare Corp, Edwards Division, Santa Ana,
Calif] or St Jude Medical valve [St Jude Medical, Inc, St Paul,
Minn]) were left to the discretion of the operating surgeon.
AVR was performed with the use of standard cardiopul-
monary bypass with moderate hemodilution (hematocrit value
20%-25%). Multidose intermittent cold blood or crystalloid
potassium cardioplegic solution was given through the aortic
root or directly into the coronary ostia. Antegrade/retrograde
delivery was also routinely used. Topical hypothermia was
used to maintain myocardial cooling. A vent was used rou-
tinely to decompress the left ventricle and achieve a bloodless
field. Careful debridement of the aortic anulus with copious
irrigation with cold (4°C) saline solution was performed to
remove all calcific debris to prevent embolization. A
Carpentier-Edwards bovine pericardial valve was used in 277
patients and a St Jude Medical mechanical valve in 89
patients. One hundred two patients received 19-mm valves
(85% pericardial valves) and 264 patients received larger
ones (72% pericardial valves). Operative mortality and mor-
bidity were carefully documented, and all patients surviving
to discharge underwent long-term follow-up.
Patient characteristics were defined as follows. Body sur-
face area (BSA) is body morphometric analysis indexing
weights and heights. Diabetes mellitus indicates a history of
diabetes, regardless of duration of disease or need for antidi-
abetic agents. Renal failure is defined as a documented fast-
ing serum creatinine level of 2.0 mg/dL. Stroke refers to a
central neurologic deficit that is unresolved at the time of pri-
mary hospital discharge. COPD is defined as the need for
pharmacologic therapy for chronic pulmonary compromise
or as a forced expiratory volume in 1 second of less than 75%
of predicted value. Ejection fraction is defined either by the
catheterization report or cardiac echocardiogram. Myocardial
infarction is defined either as the appearance of a new Q wave
in 2 or more contiguous leads on the electrocardiogram or as
clinical, angiographic, electrocardiographic, and/or laborato-
ry isoenzyme evidence of myocardial necrosis if the electro-
cardiogram shows no new Q waves. Congestive heart failure
has to fulfill at least 3 of the following criteria: presence of
dyspnea, râles thought to represent pulmonary congestion,
peripheral edema, cardiomegaly on chest x-ray film, and
chest x-ray film compatible with interstitial edema.
Reoperation includes patients who had any prior cardiac
operations. Nonelective status describes an operation that is
required during the same admission because of instability.
Severe aortic stenosis designates all cases reported as
“severe” by either preoperative catheterization or cardiac
echocardiography. CABG denotes patients whose AVR oper-
ation was combined with concomitant CABG. Ischemic time
(crossclamp time) is the total number of minutes the aorta is
completely crossclamped during bypass. Operative death
includes all deaths that occurred within 30 days of the AVR
operation or death that occurred within the same admission.
Cardiac cause of death includes the inability to wean from
cardiopulmonary bypass, low cardiac output incompatible
with life, life-threatening cardiac arrhythmia, and postopera-
tive hemorrhage. Multiorgan system failure indicates com-
promised function of 2 or more major organ systems.
Gastrointestinal etiology includes episodes of severe gas-
trointestinal hemorrhage or intestinal ischemia. Adult respi-
ratory distress syndrome includes all patients with documented
ARDS by clinical examination with or without a chest radi-
ograph. Pneumonia describes positive sputum, blood, pleural
fluid, empyema fluid, transtracheal fluid, or transthoracic
fluid cultures consistent with the diagnosis and clinical find-
ing of pneumonia or chest x-ray evidence of pulmonary infil-
trates. Sepsis is defined as an active infection with positive
blood culture. Atrial fibrillation indicates multiple atrial foci
that discharge without a single uniform atrial depolarization
documented by either monitor or electrocardiogram.
Bleeding includes all patients who required surgical explo-
ration, either in the operating room or in the intensive care
unit, for postoperative continued hemorrhage. Ventilatory
support is the number of postoperative days during which the
patients required ventilatory support, which include days in
which they are dependent at night or for periods during the
day, but does not include oxygen support with a face mask.
Intensive care unit stay refers to the number of days in the
intensive care unit before the patient is moved to the step-
down unit. 
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Statistical analysis. This is an observational study and
patients were not randomly assigned to receive valves of a
particular size; valve size was the surgeon’s choice. Thus we
evaluated the relationships between patient characteristics
and size of the implanted valve so that we might control for
the differences between the group receiving 19-mm valves
and the group receiving ‡ 21-mm valves with a propensity
score.19,20 Univariable evaluations were made with Fisher’s
exact test and the Wilcoxon rank-sum test. Characteristics
considered in calculating the propensity score were age,
BSA, diabetes, renal failure, hypertension, stroke, chronic
obstructive pulmonary disease, ejection fraction, previous
myocardial infarction, congestive heart failure, reoperation,
nonelective procedure, presence of severe aortic stenosis, and
concomitant CABG and Carpentier-Edwards valve. These
risk factors were entered into a logistic regression model to
predict receipt of a 19-mm valve. A parsimonious model was
developed, interactions among variables in that model were
examined, and finally risk factors not in the parsimonious
model were added back to account, as much as possible, for
all differences between the 2 groups. The propensity score,
then, is the probability of receiving a 19-mm valve predicted
by this final model. Patient sex was not used to calculate the
propensity score because we wanted to evaluate the relation-
ships between sex, valve size, and mortality. Multivariable
logistic regression and multivariable proportional hazards
regression were used to predict operative mortality and mor-
bidity risk and hazard of late death, respectively, associated
with small valve, patient sex, and the interaction between
small valve and sex while controlling for patient differences
via the propensity score. We performed multivariable logistic
regression analyses, again using propensity scores, to predict
operative mortality in strata of sex and valve size. We repeat-
ed our final multivariable logistic analysis 1000 times on
samples of the same size as the total sample drawn randomly
from the total sample (bootstrapping) to get a more conserv-
ative estimate of the effect of our interaction term. Statistical
analyses were performed with the use of Stata version 6 soft-
ware (Stata Corporation, College Station, Tex). 
Results
Small valve. Patients receiving small valves were
more likely to be female (91% vs 35%), older (median
age 79 vs 76 years), and smaller (median BSA 1.62 vs
1.87) than those receiving larger valves (Table I). They
were also more likely to have diabetes, to be undergo-
ing AVR as a nonelective procedure, and to be receiv-
ing a Carpentier-Edwards valve. On the other hand,
these patients were less likely to have had a stroke, to
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Table I. Demographics, risk factors, and operative characteristics of patients receiving 19-mm and ‡ 21-mm valves
Valve size
19 mm [n = 102] ‡ 21 mm [n = 264] P value*
Demographics
Female 91 (93) 35 (93) ≤.0005
Age in years, median (IQR) 79 (76-83) 76 (73-79) ≤.0005
BSA in m2, median (IQR) 1.62 (1.55-1.79) 1.87 (1.75-2.00) ≤.0005
Risk factors
Diabetes mellitus 25 (26) 21 (56) .23
Renal failure 10 (10) 11 (28) .50
Hypertension 51 (52) 55 (145) .29
Stroke 9 (9) 13 (34) .19
COPD 10 (10) 14 (37) .18
% EF, median (IQR) 60 (45-65) 55 (40-65) .02
MI 23 (23) 20 (53) .35
CHF 50 (51) 63 (166) .02
Reoperation 8 (8) 16 (42) .03
Nonelective procedure 25 (25) 18 (47) .10
Severe AS 76 (74) 77 (198) .45
Operative details
CABG 65 (66) 61 (161) .30
Crossclamp time in min, median 85 (67-106) 83 (69-106) .87
(IQR)
Carpentier-Edwards valve 85 (87) 72 (190) .10
Summary risk
Propensity score, median (IQR) 0.48 (0.28-0.69) 0.13 (0.06-0.28) ≤.0005
Outcome
Operative mortality 16.7 (17) 3.0 (8) ≤.0005
Numbers presented are column percents (n) or medians (interquartile range). IQR, Interquartile (25th-75th) range; BSA, body surface area; COPD, chronic obstruc-
tive pulmonary disease; EF, ejection fraction; MI, myocardial infarction; CHF, congestive heart failure; AS, aortic stenosis; CABG, coronary artery bypass grafting.
*Column percents compared with Fisher’s exact test and medians compared with the Wilcoxon rank-sum test.
have congestive heart failure, chronic obstructive pul-
monary disease, or a low ejection fraction, or to be
undergoing a reoperation. The final propensity score
model included age, BSA, diabetes, hypertension,
stroke, chronic obstructive pulmonary disease, ejection
fraction, congestive heart failure, reoperation, non-
elective procedure, and concomitant CABG and
Carpentier-Edwards valve. The area under the receiver
operating characteristic curve for this model was 0.83.
When the propensity score was divided into quintiles,
the propensity score for those receiving small valves
was nearly identical to that of patients receiving larger
valves within each quintile.
Women had significantly higher propensity scores for
receiving small valves than men among the small valve
group (women: 0.53, IQR 90.33-0.70; men: 0.22, IQR
0.10-0.22; P = .01). The same was true among those
receiving larger valves (women: 0.28, IQR 0.13-0.48;
men: 0.10, IQR 0.05-0.18; P ≤ .0005). In both groups,
men had significantly larger BSAs. Median BSA for
female patients (n = 186) was 1.69 m2 (IQR 1.56-1.80
m2) and for male patients (n = 180), 1.93 m2 (IQR 1.82-
2.04 m2). Interestingly, 39 patients (38%) with a mea-
sured annular size appropriate for a size 19-mm pros-
thetic valve had a BSA of 1.7 m2 or more. Specifically,
of all women who received a 19-mm valve, 34% (32/93
patients) had a BSA of 1.7 m2 or more. Among male
patients who received a 19-mm valve, 78% (7/9
patients) had a BSA of 1.7 m2 or more. 
Operative mortality. Operative death was signifi-
cantly more likely in women (72% vs 49%; P = .02), in
older patients (median age 82 vs 77 years; P = .002),
and in smaller patients (median BSA 1.69 vs 1.82 m2; P
= .008) (Table II). Risk factors for operative mortality
included diabetes mellitus, history of previous myocar-
dial infarction, and urgent/emergency status. Patients
receiving a 19-mm aortic valve prosthesis were also at
significantly increased risk for operative mortality; 68%
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Table II. Demographics, risk factors, and operative characteristics of operative deaths and survivors
Operative death
Yes [n = 25] No [n = 341] P value*
Demographics
Female 72 (18) 49 (168) .02
Age in years, median (IQR) 82 (77-83) 77 (93-80) .002
BSA in m2, median (IQR) 1.69 (1.57-1.80) 1.82 (1.67-1.98) .008
Risk factors
Diabetes mellitus 40 (10) 21 (72) .03
Renal failure 20 (5) 10 (33) .10
Hypertension 60 (15) 53 (182) .33
Stroke 16 (4) 11 (39) .34
COPD 16 (4) 13 (43) .40
% EF, median (IQR) 60 (45-68) 58 (42-65) .68
MI 36 (9) 20 (67) .05
CHF 68 (17) 59 (200) .24
Reoperation 20 (5) 13 (45) .25
Nonelective procedure 40 (10) 18 (62) .01
Severe AS 78 (18) 76 (254) .53
Operative details
CABG 68 (17) 62 (210) .34
Crossclamp time in min, median 85 (72-103) 84 (67-106) .77
(IQR)
Carpentier-Edwards valve 72 (18) 76 (259) .41
Summary risk
Propensity score, median (IQR) 0.51 (0.22-0.64) 0.18 (0.08-0.43) ≤.0005
Valve size
19 mm 68 (17) 25 (85) .001
Numbers presented are column percents (n) or medians (interquartile range). IQR, Interquartile (25th-75th) range; BSA, body surface area; COPD, chronic obstruc-
tive pulmonary disease; EF, ejection fraction; MI, myocardial infarction; CHF, congestive heart failure; AS, aortic stenosis; CABG, coronary artery bypass grafting.
Table III. Etiology of operative death categorized by
valve size 
Cause of death 19 mm ‡ 21 mm
Cardiac 8 women, 3 men 3 women, 3 men
Stroke 1 woman, 1 man 1 woman
Multiorgan system failure 2 women
Gastrointestinal 2 women 1 woman
of operative deaths occurred in patients receiving 19-
mm valves, whereas 25% of survivors received a 19-
mm valve (P = .001). The most common cause of death
was cardiac in origin in both groups (Table III).
The first multivariable model predicting operative
death (Table IV, model 1) showed that those receiving
a small valve were at increased risk of operative death
(odds ratio [OR] 5.1; 95% CI 1.6, 16; P = .006).
Contrary to expectations, though, women were at
slightly reduced risk. We constructed Table V to evalu-
ate the relationship between sex, valve size, and opera-
tive mortality. The overall mortality was higher in
women than in men (10% vs 4%; P = .02). Of more sig-
nificance, although the difference in operative mortali-
ty in women who received a 19-mm valve was signifi-
cantly higher than in women who received a larger
valve (14% vs 5%; P = .04), the difference was even
more dramatic in male patients who received a 19-mm
valve versus a ‡ 21-mm valve (44% vs 2%; P ≤ .0005).
Thus we added a sex–valve size interaction term in our
final multivariable analysis model (Table IV, model 2).
In this model, men who received a 19-mm valve were
at very high risk of operative mortality (OR 17.5; 95%
CI 2.2, 139; P = .007). Female sex and small valve also
conferred risk of operative mortality, although not to a
statistically significant degree. A likelihood ratio test
comparing model 2 with model 1 showed that the inter-
action term in model 2 added significant information
(c 2 = 7.2; df = 1; P = .007). The goodness-of-fit c 2 (df
= 8) yielded a P value of .40. In diagnostic plots, the
men receiving small valves had fairly high leverage but
were not among the observations with large Hosmer-
Lemeshow D c 2 influence or D -D influence statistics.21
However, because the interaction term is fit to 9 sub-
jects and because the confidence interval around the
estimate is so large, we were concerned about the
robustness of the finding of significantly increased risk.
Consequently, we fit additional multivariable logistic
models in strata of valve size and sex (Table IV, mod-
els 3-6). Each model was fit with a propensity score
derived in its stratum. The number of events and
patients is much smaller in the strata, such that confi-
dence intervals are considerably larger, but men are at
a 6.5-fold increased risk of operative mortality among
patients receiving 19-mm valves (model 3), and among
men, those receiving 19-mm valves are at a 42-fold risk
The Journal of Thoracic and
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Table IV. Odds ratio (95% CI for operative mortality)
Model Population Variables in the model OR (95% CI) P value
1 All patients (n = 366) 19-mm valve 5.1 (1.6, 16) .006
Female sex 0.6 (0.2, 2.2) .47
Propensity score 5.3 (0.7, 39) .10
2 All patients (n = 366) 19-mm valve 2.1 (0.7, 6.4) .21
Female sex 2.2 (0.5, 10.2) .30
Male sex + 19-mm valve 17.5 (2.2, 139) .007
Propensity score 5.9 (0.8, 43) .08
3 All 19-mm valves (n = 102) Male sex 6.5 (1.4, 31) .02
Propensity score 4.4 (0.3, 62) .27
4 All ‡ 21-mm valves (n = 264) Male sex 0.3 (0.1, 1.9) .23
Propensity score 0.7 (0.3, 16) .83
5 All women (n = 186) 19-mm valve 1.9 (0.6, 6.0) .30
Propensity score 9.7 (0.7, 134) .09
6 All men (n = 180) 19-mm valve 42 (4.8, 384) .001
Propensity score 1.4 (0, 1277) .95
7 All patients (n = 366) 19-mm valve 1.2 (0.3, 4.4) .81
Female sex 1.9 (0.4, 9.7) .46
Male sex + 19-mm valve 12.2 (1.2, 122) .03
Propensity score 8.7 (0.7, 104) .09
BSA < 1.7 m2 3.4 (0.7, 17.5) .14
BSA ‡ 1.7 m2 + 19-mm valve 3.1 (0.4, 23) .26
OR, Odds ratio; CI, confidence interval; BSA, body surface area.
Table V. Percent of patients who died (n deaths/n at
risk) in strata of valve size and sex
Valve size
All patients, % 19 mm, % ‡ 21 mm, % 
(n deaths/ (n deaths/ (n deaths/
n at risk) n at risk) n at risk) P value
Female 10 (18/186) 14 (13/93) 5 (5/93) .04
Male 4 (7/180) 44 (4/9) 2 (3/171) ≤.0005
P value .02
of operative mortality (model 6). In addition, the medi-
an odds ratio for the interaction term in model 2 calcu-
lated from the bootstrapping procedure was 18.5. The
odds ratio at the 5th percentile was 2.4, indicating that
95% of the time the odds for operative death for men
receiving a 19-mm valve in this sample is 2.4 or
greater.
We remained concerned that the male–small valve
interaction reflected valve mismatch. We fit a final
model that included terms for BSA less than 1.7 m2 and
interaction between small valve and BSA of 1.7 m2 or
more to see whether these would displace the
male–small valve term (Table IV, model 7). Men
receiving small valves continued to be at significantly
increased risk of operative death (OR 12.2; 95% CI 1.2,
122; P = .03). Both BSA terms had odds ratios of about
3. Although it did not reach statistical significance,
there is the suggestion that valve mismatch may confer
additional risk of operative death. However, this model
really stretches the data; confidence intervals are large.
In diagnostic plots, the men receiving small valves,
however, had leverage similar to that in the earlier
model, and the Hosmer-Lemeshow D c 2 influence and
D -D influence statistics for other observations that were
large before were still larger.
Morbidity. Postoperative morbidity was evaluated in
all patients (Table VI), and models included the propen-
sity score. Patients who received a 19-mm prosthetic
valve were at increased risk of prolonged intensive care
unit stay (‡ 72 hours) (OR 1.8; 95% CI 0.99, 3.4; P =
.05). A small valve did not appear to confer risk of any
other morbidity, although a number of morbidities, par-
ticularly adult respiratory distress syndrome and sepsis,
occurred infrequently. 
Late death. All 341 patients who survived to dis-
charge were observed in the postoperative period, with
a median follow-up time of 24 months (80% of these
patients have been contacted within the past 6 months).
Survival at 24 months after the operation was 90% ±
4% (n = 50) in patients who received 19-mm valves and
91% ± 2% (n = 131) in patients who received ‡ 21-mm
valves. Survival at 48 months after the operation was
85% ± 5% (n = 20) in patients who received 19-mm
valves and 81% ± 4% (n = 43) in patients who received
‡ 21-mm valves. In the univariable proportional hazards
model, 19-mm valve was not related to late death (haz-
ard ratio 1.0; 95% CI 0.5, 2.0; P = .95). In the multi-
variable model that included a propensity score, there
continued to be no difference in hazard of death
between patients receiving 19-mm valves and those
receiving ‡ 21-mm valves (hazard ratio 0.7; 95% CI
0.3; 1.8; P = .51).
Discussion
Optimal surgical management of aortic valve steno-
sis in elderly patients with a small aortic root remains
highly controversial. In the past, small aortic valve
prostheses were believed to have poor hemodynamic
performance and were therefore used sparingly.22,23
Aortic root enlargement was popularized as a means to
allow implantation of larger prosthetic valves, thus
minimizing the risk of significant patient-prosthesis
mismatch.15,16,22 When newer generation prosthetic
valves with better performance became available in
small sizes, many groups, including our own, chose to
implant them in patients.5,9,24-27
No randomized studies have been done to answer the
question whether a patient with a small aortic anulus is
better treated by insertion of a 19-mm prosthetic valve
or by root enlargement with insertion of a larger valve.
Several recent studies have attempted to clarify the
consequences of inserting a small prosthetic aortic
valve. Unfortunately, many of these studies have
included patients undergoing valve replacement for
aortic insufficiency or patients undergoing concomitant
mitral valve replacement,5,28 which complicates com-
parisons of reported outcomes.29 We limited our study
to elderly patients with stenotic aortic disease with or
without coronary artery disease in an attempt to identi-
fy a homogeneous cohort. 
We were surprised to identify a significant increase
in operative mortality among patients receiving a size
19-mm prosthetic valve. The selective impact of 19-
mm valve insertion on operative mortality was eluci-
dated only after we identified the subgroup at risk:
elderly male patients with a measured 19-mm anulus.
Medalion and associates5 recently published their
experience with insertion of small aortic valves in octo-
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Table VI. Odds ratio (95% CI) for operative morbidity
for receipt of 19-mm valve; all models included a
propensity score
Morbidity No. of events OR (95% CI) P value
Stroke 25 1.2 (0.4, 3.3) .78
Renal failure 19 1.4 (0.4, 4.4) .62
ARDS 3 0.4 (0, 5.9) .46
Pneumonia 22 1.2 (0.4, 3.8) .80
Sepsis 11 1.9 (0.4, 9.1) .43
Atrial fibrillation 150 1.1 (0.6, 2.0) .75
Bleeding 31 1.7 (0.6, 5.1) .34
Ventilatory support 96 0.9 (0.5, 1.9) .86
‡ 24 h
ICU stay ‡ 72 h 98 1.8 (0.99, 3.5) .05
Hospital stay ‡ 10 d 105 0.8 (0.4, 1.6) .52
OR, Odds ratio; CI, confidence interval; ARDS, adult respiratory distress syn-
drome; ICU, intensive care unit.
genarians and noted patients receiving 19-mm valves
exhibited a trend toward a higher operative mortality,
but they did not specifically address differences related
to sex. The factors responsible for the poor outcome in
our male subgroup remain unclear. Certainly size mis-
match may have been an important variable given 7 of
9 men who received a 19-mm prosthesis had a BSA of
1.7 m2 or more. It should be noted that women with a
BSA of 1.7 m2 or more who received a 19-mm valve
were not at increased risk for mortality. It is also possi-
ble that the poor outcome observed in men did not
result directly from the hemodynamic consequence of
19-mm valve insertion. The presence of a small anulus
may be a marker for other undefined risk factors that
may in a collective manner adversely affect outcome in
men more than women. It is known, for example, that
there are differences related to sex in left ventricular
adaptation to aortic stenosis, and in general abnormal
myocardial architecture and ventricular dysfunction are
more commonly observed in men.30 Furthermore,
Morris and associates4 demonstrated a positive inde-
pendent effect of female sex on recovery of left ven-
tricular ejection fraction after AVR. Recently, Cohen
and colleagues31 have also reported that male sex has a
negative impact on late survival after bioprosthetic
AVR. Our subgroup of men receiving 19-mm valves is
too small to enable us to draw specific conclusions, but
our observation of increased operative mortality war-
rants further investigation. 
Although data regarding postoperative prosthetic
transvalvular gradients and calculated effective valve
orifice areas vary widely, the consensus is that patients
surviving insertion of a small prosthetic valve are left
with a fixed degree of left ventricular outflow tract
obstruction. As a result, the regression of left ventricu-
lar hypertrophy is slower than in recipients of larger
valves.1,2,11 The impact of persistent prosthetic outflow
obstruction on late survival is controversial and has
been previously addressed by several investigators.
Kratz and associates3 reported that patients with a BSA
of more than 1.9 m2 who received a 19-mm St Jude
Medical aortic valve were more likely to experience
late sudden death. He and colleagues24 noted that
patient-prosthesis size mismatch (≤21-mm size pros-
thetic valve with BSA > 1.7) in the setting of concomi-
tant CABG was a negative determinant for long-term
survival. In contrast, Sawant and associates8,9 found no
correlation between insertion of a 19-mm St Jude
Medical valve and BSA with late mortality. Similarly,
Medalion and coworkers5 found that long-term survival
was unaffected by the combination of 19-mm prosthet-
ic valve and BSA more than 1.7 m2. We did not observe
a higher late mortality in our patients receiving 19-mm
prostheses regardless of BSA, but our follow-up
remains relatively short. 
Our findings have caused us to think carefully about
our use of standard 19-mm aortic prostheses in elderly
men. Although the number of patients in this subgroup
is extremely small (9/366 patients), it is hard to ignore
their poor outcome. It would appear that a higher per-
formance valve, such as a homograft or stentless valve,
and/or root enlargement procedure should be consid-
ered in men with a measured 19-mm anulus. Ongoing
trials with higher performance valves in elderly
patients may identify other subgroups that would bene-
fit from similar management. 
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Discussion
Dr Donald B. Doty (Salt Lake City, Utah). Dr Adams and
his associates at the Brigham and Women’s Hospital in Boston
have presented data that attempt to answer the ongoing con-
troversy of whether a small prosthetic valve, 19 mm in diam-
eter, should be implanted in adult patients. We have already
heard from the Cleveland Clinic that a 19-mm valve is fine
and that mismatch between prosthetic size and body size
makes no difference in short- or long-term patient survival. 
What seems to have caught Dr Adams’ attention is an
excessively high operative mortality of 16.7% when a 19-mm
prosthesis was used to replace the stenotic aortic valve. This
is 5 times higher than the 3% mortality when larger valves
were used. The rate was 14% in women and even worse when
a 19-mm valve was used in men: 4 of 9, or 44%, died. The
authors conclude that insertion of a 19-mm prosthesis carries
a substantial risk of death, especially in men, but also in
women, and advised aortic root enlargement or perhaps the
use of a stentless prosthesis. 
I agree with this conclusion and would extend it a few more
steps. We are presently using stentless porcine valve prosthe-
ses in nearly all patients over the age of 70 years because of
superior hemodynamic performance. In situations in which
mechanical prostheses are indicated, we do not use 19-mm
valves at all and only use 21-mm prostheses in patients who
have a BSA less than 1.5 m2 and who are sedentary. This is
standard textbook policy. 
In the original abstract, I noted that operative mortality was
doubled in the 21-mm valves. Dr Adams, would you com-
ment on how 21-mm valves should be used in practice? 
Dr Adams. Thank you, Dr Doty. On the basis of our data,
I would implant a 21-mm valve without hesitation, except
perhaps in an extremely large patient. We did find a doubling
of operative mortality with univariable analysis of 21-mm
valves, but we later combined 21-mm and larger valves
because there was little difference in their operative outcome
once multiple variables were taken into account.
We are not ready to join you in abandoning the use of 19-
mm valves, but we will be using fewer of them in elderly
men. In general, stentless valve or root enlargement proce-
dures are more tedious, and I think we will continue to per-
form the simplest operation possible in most patients. I
believe the “standard” textbook policy” you referred to may
need to be revised. Ongoing randomized studies comparing
stentless and stented valves, particularly in the smaller valve
size groups, should clarify optimal patient/valve matching.
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